Surmodics Statistics
Total Valuation
Surmodics has a market cap or net worth of $598.55 million. The enterprise value is $587.09 million.
| Market Cap | 598.55M |
| Enterprise Value | 587.09M |
Important Dates
The next estimated earnings date is Wednesday, July 31, 2024, before market open.
| Earnings Date | Jul 31, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Surmodics has 14.26 million shares outstanding. The number of shares has increased by 1.08% in one year.
| Shares Outstanding | 14.26M |
| Shares Change (YoY) | +1.08% |
| Shares Change (QoQ) | +0.57% |
| Owned by Insiders (%) | 3.74% |
| Owned by Institutions (%) | 96.09% |
| Float | 9.55M |
Valuation Ratios
The trailing PE ratio is 43.72.
| PE Ratio | 43.72 |
| Forward PE | n/a |
| PS Ratio | 4.19 |
| Forward PS | 4.56 |
| PB Ratio | 4.83 |
| P/FCF Ratio | 26.54 |
| PEG Ratio | 3.90 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.36, with an EV/FCF ratio of 26.03.
| EV / Earnings | 43.49 |
| EV / Sales | 4.11 |
| EV / EBITDA | 19.36 |
| EV / EBIT | 28.15 |
| EV / FCF | 26.03 |
Financial Position
The company has a current ratio of 4.39, with a Debt / Equity ratio of 0.24.
| Current Ratio | 4.39 |
| Quick Ratio | 2.77 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | 0.97 |
| Debt / FCF | 1.31 |
| Interest Coverage | 5.87 |
Financial Efficiency
Return on equity (ROE) is 11.30% and return on invested capital (ROIC) is 9.82%.
| Return on Equity (ROE) | 11.30% |
| Return on Assets (ROA) | 7.30% |
| Return on Capital (ROIC) | 9.82% |
| Revenue Per Employee | $380,221 |
| Profits Per Employee | $35,907 |
| Employee Count | 376 |
| Asset Turnover | 0.78 |
| Inventory Turnover | 2.05 |
Taxes
In the past 12 months, Surmodics has paid $3.80 million in taxes.
| Income Tax | 3.80M |
| Effective Tax Rate | 21.97% |
Stock Price Statistics
The stock price has increased by +35.65% in the last 52 weeks. The beta is 1.18, so Surmodics's price volatility has been higher than the market average.
| Beta (5Y) | 1.18 |
| 52-Week Price Change | +35.65% |
| 50-Day Moving Average | 36.54 |
| 200-Day Moving Average | 33.01 |
| Relative Strength Index (RSI) | 77.07 |
| Average Volume (20 Days) | 434,501 |
Short Selling Information
The latest short interest is 605,507, so 4.25% of the outstanding shares have been sold short.
| Short Interest | 605,507 |
| Short Previous Month | 512,973 |
| Short % of Shares Out | 4.25% |
| Short % of Float | 6.34% |
| Short Ratio (days to cover) | 1.51 |
Income Statement
In the last 12 months, Surmodics had revenue of $142.96 million and earned $13.50 million in profits. Earnings per share was $0.96.
| Revenue | 142.96M |
| Gross Profit | 113.10M |
| Operating Income | 19.30M |
| Pretax Income | 17.30M |
| Net Income | 13.50M |
| EBITDA | 30.32M |
| EBIT | 20.86M |
| Earnings Per Share (EPS) | $0.96 |
Balance Sheet
The company has $40.94 million in cash and $29.48 million in debt, giving a net cash position of $11.46 million or $0.80 per share.
| Cash & Cash Equivalents | 40.94M |
| Total Debt | 29.48M |
| Net Cash | 11.46M |
| Net Cash Per Share | $0.80 |
| Equity (Book Value) | 123.95M |
| Book Value Per Share | 8.69 |
| Working Capital | 65.07M |
Cash Flow
In the last 12 months, operating cash flow was $25.76 million and capital expenditures -$3.21 million, giving a free cash flow of $22.56 million.
| Operating Cash Flow | 25.76M |
| Capital Expenditures | -3.21M |
| Free Cash Flow | 22.56M |
| FCF Per Share | $1.59 |
Margins
Gross margin is 79.11%, with operating and profit margins of 13.50% and 9.44%.
| Gross Margin | 79.11% |
| Operating Margin | 13.50% |
| Pretax Margin | 12.10% |
| Profit Margin | 9.44% |
| EBITDA Margin | 21.21% |
| EBIT Margin | 14.59% |
| FCF Margin | 15.78% |
Dividends & Yields
Surmodics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.08% |
| Shareholder Yield | -1.08% |
| Earnings Yield | 2.26% |
| FCF Yield | 3.77% |
Analyst Forecast
The average price target for Surmodics is $43.00, which is 2.45% higher than the current price. The consensus rating is "Hold".
| Price Target | $43.00 |
| Price Target Difference | 2.45% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on December 7, 2000. It was a forward split with a ratio of 2:1.
| Last Split Date | Dec 7, 2000 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Surmodics has an Altman Z-Score of 8.35 and a Piotroski F-Score of 7.
| Altman Z-Score | 8.35 |
| Piotroski F-Score | 7 |